Submitted by Anonymous (not verified) on 22 March 2024 - 13:45
Human medicines European public assessment report (EPAR): Rayvow, lasmiditan, Date of authorisation: 17/08/2022, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rayvow, lasmiditan, Date of authorisation: 17/08/2022, Revision: 3, Status: Authorised